Silver Nitrate Application and Topical Corticosteroids for Hypergranulation Tissue
NCT ID: NCT02398539
Last Updated: 2015-05-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
50 participants
INTERVENTIONAL
2015-04-30
2016-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Maximum duration of therapy is 4 weeks. However, the therapy may be discontinued anytime at the discretion of the investigator or if there is resolution of the of the hypergranulation tissue.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
Silver nitrate treatment will include weekly applications in the pediatric surgery office by a clinician.
Silver Nitrate
Silver Nitrate Sticks
Group 2
Triamcinolone cream, 0.5% applied three times per day by the patient's caregiver.
Triamcinolone
0.5% cream
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Silver Nitrate
Silver Nitrate Sticks
Triamcinolone
0.5% cream
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Evaluated for hypergranulation at the G-tube site
3. Inpatient and out-patient
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Akron Children's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Eloise Lemon
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Akron Children's Hospital
Akron, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Eloise Lemon
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
150110
Identifier Type: -
Identifier Source: org_study_id